worldwide offices | contact | help | sitemap

 

 

 

 

Newsroom

Newsroom

Vaccination of University of California, Santa Barbara Community

Novartis discovered and developed Bexsero®, (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), the first and only vaccine to help protect all age groups against this disease. Bexsero was approved in Europe and Australia and approvals in other countries are expected soon. Novartis is collaborating with the Centers for Disease Control (CDC) and University of California, Santa Barbara to make Bexsero available to members of the UCSB community as recommended by the CDC.



CDC - Serogroup B Meningococcal Vaccine Questions and Answers

UCSB – Meningitis Health Alert

 

 

Fact Sheets on Bexsero and Meningococcal Disease

US Meningococcal Disease Fact Sheet

Bexsero Fact Sheet


Meningococcal Disease Fact Sheet


Untold Toll of Meningococcal Disease Fact Sheet


Value of Vaccines Fact Sheet


 

 

Infographics

Bexsero R&D Timeline

Meningococcal Disease: A Story by Numbers

 

 

Images

Bexsero Logo

Bexsero Logo

All rights reserved.

Bexsero Package Image

Bexsero Package Image

All rights reserved.

Bexsero Package Image

Bexsero Package Image 2

All rights reserved.

Bexsero Package Image

Bexsero Package Image 3

All rights reserved.

Bexsero Package Image

Bexsero Package Image 4

All rights reserved.

Meningitis Bacteria

Meningitis Bacteria

All rights reserved.

 

About Novartis Vaccines

vaccines

Novartis Vaccines is the world's fifth-largest vaccines business.